Want to Buy the Dip on Eli Lilly? Consider This Low-Cost Vanguard ETF

Eli Lilly is down 15.6% YTD and its GLP-1 drugs Mounjaro and Zepbound drove a combined 56% of revenue in 2025 (up from 36.7% in 2024), concentrating growth risk. The stock trades at a trailing P/E of 40.1 and a forward P/E of 26.1, leaving valuation sensitive to pricing, competition, and FDA decisions. For diversified exposure, Vanguard Healthcare ETF (VHT) holds a 12.6% position in Lilly, has a P/E of 25.3, 1.6% yield and a 0.09% expense ratio, and is presented as a lower-risk alternative for balanced investors.

Analysis

The market is treating concentrated GLP-1 exposure as a convex bet: upside if pricing and adoption stay structurally intact, downside if payers or competitors bite. The real second-order beneficiaries are the outsourced manufacturing and fill/finish complex (companies that scale volumes quickly) and large diversified healthcare ETFs that dilute single-company execution risk; counterparties who provide distribution and patient access (PBMs, specialty clinics) will see re‑rated flows as utilization patterns change.

Key catalysts span multiple horizons: in the near term (days–weeks) earnings prints and any manufacturer commentary on supply/sales cadence will drive volatile re-rating; over 3–12 months payer policy memos or formulary edits (national PBM/insurer guidance) are the highest probability paths to revenue moderation; over 12–36 months new entrants, label expansions, or regulatory pricing actions create asymmetric downside tail risk. A material pricing pushback or a swift market-share loss to a competitor would compress earnings multiples quickly and is the primary path to a >30% drawdown in the incumbent’s equity.

From a positioning perspective, prefer exposure to structural demand for obesity care while avoiding single-company execution risk. Use ETFs or exposure to the manufacturing and distribution nodes to capture upside from higher category growth without concentrated product risk. Also keep a tactical allocation to asymmetric downside protection on the largest names in case of rapid policy or competition shocks — the convexity profile favors modest option spend over outright concentrated longs.

Key Decisions for Investors

• Pair trade (3–12 months): Long Vanguard Healthcare ETF (VHT) vs short Eli Lilly (LLY) 1:0.25 notional (size VHT > LLY to reflect diversification). R/R: target +12–18% on VHT relative to LLY; stop if relative move against position >10%. Rationale: capture sector upside while hedging single‑name concentration risk.
• Manufacturing play (6–18 months): Buy Catalent (CTLT) equity or Feb(>6mo) call spreads to express continued GLP-1 volume tailwinds. R/R: expect 20–40% upside if outsourcing demand persists; downside limited by diversified clinical-services revenue. Use 1/3 position size vs core healthcare exposure.
• Protective options (6–9 months): Buy LLY 6–9 month puts or put spreads (ATM to 10% OTM) sized to cap 20–30% of portfolio exposure to the sector. R/R: modest premium protects against policy/competition shocks that can produce rapid >25% downside.
• Contrarian tactical (9–18 months): If LLY pulls back >20% on headline fear, enter a long LLY call spread (12‑month) to capture mean reversion in pricing power while limiting downside. R/R: asymmetric payoff — small premium for 2–4x upside if secular demand persists and company reasserts pricing/execution.